Montelukast Teva (Montelukast Sodium)

Montelukast Sodium, the active ingredient in Montelukast Teva, is a leukotriene receptor antagonist presented as an oral formulation for oral use. It treats asthma, exercise‑induced bronchoconstriction and allergic rhinitis in adults and children.

GNH USA supplies Montelukast Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast Teva is a leukotriene receptor antagonist used in respiratory and allergic disorders.

- Asthma: improves control of chronic asthma and reduces the frequency of exacerbations. - Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs during physical activity. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching caused by seasonal allergies.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain in the head. - Abdominal pain: discomfort or cramps in the stomach area. - Nausea: feeling of queasiness or urge to vomit. - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: unusual tiredness or lack of energy. - Cough: transient irritation of the throat.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema or anaphylaxis. - Neuropsychiatric events: mood changes, depression or suicidal thoughts. - Hepatic enzyme elevation: abnormal liver function tests. - Eosinophilic granulomatosis with polyangiitis: rare vasculitic disorder. - Stevens‑Johnson syndrome: severe skin and mucous membrane reaction. - Blood dyscrasias: rare cases of neutropenia or thrombocytopenia.

Before initiating therapy, clinicians should consider several safety aspects.

- Liver function assessment: evaluate hepatic status, especially in patients with known liver disease. - Neuropsychiatric monitoring: watch for mood changes, depression or suicidal ideation. - Hypersensitivity: avoid in individuals with known allergy to montelukast or any tablet excipients. - Pediatric dosing: follow age‑specific recommendations provided by the prescriber. - Drug interactions: review concomitant medications that may affect montelukast metabolism. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Montelukast may interact with other medicines that influence its metabolism or pharmacodynamic profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase montelukast plasma concentrations. - Rifampin or other potent CYP inducers: may markedly reduce therapeutic effect. - Phenobarbital: can lower montelukast levels, compromising efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: occasional reports of altered INR; monitor coagulation parameters. - Phenylephrine or pseudoephedrine: may increase risk of cardiovascular side effects. - Theophylline: monitor for additive bronchospastic effects. - Antidepressants (SSRIs): observe for enhanced neuropsychiatric symptoms.